Progesterone promotes immunomodulation and tumor development in the murine mammary gland
Abstract
Clinical studies have linked usage of progestins (synthetic progesterone [P4]) to breast cancer risk. However, little is understood regarding the role of native P4, signaling through the progesterone receptor (PR), in breast tumor formation. Recently, we reported a link between PR and immune signaling pathways, showing that P4/PR can repress type I interferon signaling pathways. Given these findings, we sought to investigate whether P4/PR drive immunomodulation in the mammary gland and promote tumor formation.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- May 01, 2021
- Source ID
- 10.1136/jitc-2020-001710
Entities
People
- Alfredo A Molinolo
- Carol A Lange
- Christy R Hagan
- Dominika E. Helm
- Gangjun Lei
- Gloria M. Trinca
- Howard H Yang
- Junping Wei
- Justin M. Balko
- Katelin A. Gibson
- Katherine R Walter
- Kent W Hunter
- Lauryn R. Werner
- Margaret L Axelrod
- Mary A Markiewicz
- Merit L. Goodman
- Prabhakar Chalise
- Rashna Madan
- Richard C Hastings
- Sean M. Holloran
- Xiao-yi Yang
- Ying Hu
- Zachary C Hartman
Organizations
- National Cancer Institute
- National Institutes of Health
- Susan G. Komen for the Cure
- United States Department of Defense
- V Foundation for Cancer Research